Evidence map›Paper›PMID 35767180›Full record

ReviewJournal of physiology and biochemistry2023

The role of microRNAs in the modulation of cancer-associated fibroblasts activity during pancreatic cancer pathogenesis.

Lawrence N Barrera, P Matthew Ridley, Camino Bermejo-Rodriguez, Eithne Costello, Pedro A Perez-Mancera

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of physiology and biochemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Lawrence N BarreraDepartment of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
P Matthew RidleyDepartment of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
Camino Bermejo-RodriguezDepartment of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
Eithne CostelloDepartment of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK. ecostell@liverpool.ac.uk.
Pedro A Perez-ManceraDepartment of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK. pedro.perez-mancera@liverpool.ac.uk.
University of Liverpool · GB

Funding

Cancer Research UK C7690/A26881Hampson Trust A0873/CFNational Centre for the Replacement, Refinement and Reduction of Animals in Research NC/V001167/1
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the deadliest of the common cancers. A major hallmark of PDAC is an abundant and dense fibrotic stroma, the result of a disproportionate deposition of extracellular matrix (ECM) proteins. Cancer-associated fibroblasts (CAFs) are the main mediators of PDAC desmoplasia. CAFs represent a heterogenous group of activated fibroblasts with different origins and activation mechanisms. microRNAs (miRNAs) are small non-coding RNAs with critical activity during tumour development and resistance to chemotherapy. Increasing evidence has revealed that miRNAs play a relevant role in the differentiation of normal fibroblasts into CAFs in PDAC. In this review, we discuss recent findings on the role of miRNAs in the activation of CAFs during the progression of PDAC and its response to therapy, as well as the potential role that PDAC-derived exosomal miRNAs may play in the activation of hepatic stellate cells (HSCs) and formation of liver metastasis. Since targeting of CAF activation may be a viable strategy for PDAC therapy, and miRNAs have emerged as potential therapeutic targets, understanding the biology underpinning miRNA-mediated tumour cell-CAF interactions is an important component in guiding rational approaches to treating this deadly disease.

Indexed as

Cancer-Associated FibroblastsCarcinoma, Pancreatic DuctalMicroRNAsPancreatic NeoplasmsHumansMicroRNAsCancer-associated fibroblasts (CAFs)microRNAsPancreatic cancerResponse to therapyTumour pathogenesis

Identifiers

PMID35767180
PMCPMC9905185
OpenAlexW4283705141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.